Respiratory Syncytial Virus Infection

Respiratory
8
Pipeline Programs
4
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
1
1
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
350%
Vaccine
233%
RNA Therapeutic
117%
+ 5 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
4 programs
1
1
PalivizumabPhase 3Monoclonal Antibody1 trial
palivizumabPhase 2/3Monoclonal Antibody1 trial
Surveillance of Synagis in Korean Pediatric PatientsN/A1 trial
SynagisN/A1 trial
Active Trials
NCT01537198Completed618Est. Jun 2014
NCT01107535Completed82Est. Feb 2011
NCT01006629Completed100Est. Jul 2010
+1 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
PalivizumabPhase 3Monoclonal Antibody1 trial
Surveillance of Synagis in Korean Pediatric PatientsN/A
Active Trials
NCT02282982Completed359Est. May 2015
Vigonvita
VigonvitaChina - Suzhou
1 program
1
Deuremidevir Hydrobromide for SuspensionPhase 21 trial
Active Trials
NCT06206720CompletedEst. Jun 2025
Sanofi
SanofiPARIS, France
4 programs
3
1
RSV/hMPV vaccine candidate Dose LPhase 1/2Vaccine1 trial
ALX-0171Phase 11 trial
RSV/hMPV mRNA LNP 1Phase 1RNA Therapeutic1 trial
parainfluenza virus type 3 vaccinePhase 1Vaccine1 trial
Active Trials
NCT01909843Completed24Est. Dec 2013
NCT06237296Completed558Est. Feb 2025
NCT06604767Active Not Recruiting390Est. Mar 2026
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbottPalivizumab
Abbottpalivizumab
VigonvitaDeuremidevir Hydrobromide for Suspension
SanofiRSV/hMPV vaccine candidate Dose L
Sanofiparainfluenza virus type 3 vaccine
SanofiRSV/hMPV mRNA LNP 1
SanofiALX-0171
AbbViePalivizumab
AbbottSurveillance of Synagis in Korean Pediatric Patients
AbbottSynagis

Clinical Trials (10)

Total enrollment: 2,805 patients across 10 trials

NCT01466062AbbottPalivizumab

Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions

Start: Aug 2011Est. completion: Apr 201228 patients
Phase 3Completed
NCT01006629Abbottpalivizumab

Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

Start: Nov 2009Est. completion: Jul 2010100 patients
Phase 2/3Completed
NCT06206720VigonvitaDeuremidevir Hydrobromide for Suspension

A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSV

Start: Jan 2024Est. completion: Jun 2025
Phase 2Completed
NCT06134648SanofiRSV/hMPV vaccine candidate Dose L

Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate

Start: Nov 2023Est. completion: Feb 2026646 patients
Phase 1/2Completed
NCT06604767Sanofiparainfluenza virus type 3 vaccine

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

Start: Sep 2024Est. completion: Mar 2026390 patients
Phase 1Active Not Recruiting
NCT06237296SanofiRSV/hMPV mRNA LNP 1

Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

Start: Jan 2024Est. completion: Feb 2025558 patients
Phase 1Completed
NCT01909843SanofiALX-0171

ALX-0171 Safety Study in Adults With Hyperresponsive Airways

Start: Jul 2013Est. completion: Dec 201324 patients
Phase 1Completed
NCT02282982AbbViePalivizumab

Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis

Start: Oct 2014Est. completion: May 2015359 patients
N/ACompleted
NCT01537198AbbottSurveillance of Synagis in Korean Pediatric Patients

Surveillance of Synagis in Korean Pediatric Patients

Start: Jan 2012Est. completion: Jun 2014618 patients
N/ACompleted
NCT01107535AbbottSynagis

Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection

Start: Sep 2007Est. completion: Feb 201182 patients
N/ACompleted

Related Jobs in Respiratory

Ausbildung zum Pharmakanten (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
20h ago

Global Senior Medical Director – Respiratory Pipeline Medical Lead

Pfizer
United States - New York - New York City
Yesterday
$275K - $458K/yr

Praktikant (m/w/d) Marketing Onkologie

Amgen
Germany - Munich
Yesterday

Sr Product Manager, Monarch (1 of 2)

Johnson & Johnson
Santa Clara, California, United States of America
Yesterday
$142K - $245K/yr

Laboratory Assistant (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Director Quality Control (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space

Related Indications

Asthma(378)Pulmonary Disease, Chronic Obstructive(263)Chronic Obstructive Pulmonary Disease(123)Idiopathic Pulmonary Fibrosis(90)COPD(74)Chronic Obstructive Pulmonary Disease (COPD)(38)Pulmonary Embolism(27)Respiratory Syncytial Virus Infections(26)Severe Asthma(21)Lung Diseases, Interstitial(19)